Optimal-Transport Analysis of Single-Cell Gene Expression Identifies Developmental Trajectories in Reprogramming
- PMID: 30712874
- PMCID: PMC6402800
- DOI: 10.1016/j.cell.2019.01.006
Optimal-Transport Analysis of Single-Cell Gene Expression Identifies Developmental Trajectories in Reprogramming
Erratum in
-
Optimal-Transport Analysis of Single-Cell Gene Expression Identifies Developmental Trajectories in Reprogramming.Cell. 2019 Mar 7;176(6):1517. doi: 10.1016/j.cell.2019.02.026. Cell. 2019. PMID: 30849376 Free PMC article. No abstract available.
Abstract
Understanding the molecular programs that guide differentiation during development is a major challenge. Here, we introduce Waddington-OT, an approach for studying developmental time courses to infer ancestor-descendant fates and model the regulatory programs that underlie them. We apply the method to reconstruct the landscape of reprogramming from 315,000 single-cell RNA sequencing (scRNA-seq) profiles, collected at half-day intervals across 18 days. The results reveal a wider range of developmental programs than previously characterized. Cells gradually adopt either a terminal stromal state or a mesenchymal-to-epithelial transition state. The latter gives rise to populations related to pluripotent, extra-embryonic, and neural cells, with each harboring multiple finer subpopulations. The analysis predicts transcription factors and paracrine signals that affect fates and experiments validate that the TF Obox6 and the cytokine GDF9 enhance reprogramming efficiency. Our approach sheds light on the process and outcome of reprogramming and provides a framework applicable to diverse temporal processes in biology.
Keywords: ancestors; descendants; development; iPSCs; optimal-transport; paracrine interactions; regulation; reprogramming; scRNA-seq; trajectories.
Copyright © 2019 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests:
GS, JS, MT, BC, AR, EL and PR are named inventors on International Patent Application No PCT/US2018/051808 relating to work of this manuscript.
AR is a founder of Celsius Therapeutics and a member of the SAB of Syros Pharmaceuticals, Driver Group and ThermoFisher Scientific.
ESL serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he also serves on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy.
Figures
References
-
- Aigner L, and Bogdahn U (2008). TGF-beta in neural stem cells and in tumors of the central nervous system. Cell and Tissue Research 331, 225–241 - PubMed
-
- Ambrosio L, Gigli N, and Savaré G (2008). Gradient flows in metric spaces and in the space of probability measures. Springer.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
